Windtree Therapeutics

Windtree Therapeutics Preclinical Study Results Show Potential for KL4 Surfactant as Possible Medical Countermeasure to Radiation Exposure

Authors:
Steven Giannos
Date:
PRNewswire: November 3, 2016 – WARRINGTON, PA, U.S.A. – Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that recently presented preclinical data at the 62nd Radiation Research…

join_crs.jpg